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Abstract: Gum Arabic (GA) is a widely-used additive in food processing, but is also historically
used in a number of traditional therapies. It has been shown to have a broad range of health
benefits, particularly in improving important cardiovascular risk indicators. Metabolic syndrome
and its associated cardiac outcomes are a significant burden on modern healthcare systems, and
complementary interventions to aid in its management are required. We aimed to examine the
effect of GA on those with, or at risk of, metabolic syndrome to identify an effect on improving
important disease parameters related to cardiovascular outcomes. A single-blind, randomized,
placebo-controlled trial was conducted to identify the effects of daily GA supplementation on
metabolic and cardiovascular risk factors. A total of 80 participants were randomized to receive
20 g of GA daily (n = 40) or placebo (1 g pectin, n = 40) for 12 weeks. Key endpoints included
body-anthropometric indices, diet and physical activity assessment, and blood chemistry (HbA1c,
fasting glucose, and blood lipids). Of the 80 enrolled, 61 completed the study (intervention: 31,
control: 30) with 19 dropping out due to poor treatment compliance. After 12 weeks, the participants
receiving the GA showed significant decreases in systolic and diastolic blood pressure, fat-free body
mass, energy and carbohydrate consumption, and fasting plasma glucose, as well as increased
intake of dietary fiber. They also reported improvements in self-perceived bloating and quality of
bowel movements, as well as a decreased appetite score following GA consumption. These results
suggest that GA could be a safe and beneficial adjunct to other treatments for those with, or at risk of,
metabolic syndrome.
Keywords: metabolic syndrome; Gum Arabic; Acacia senegal; Acacia seyal
1. Introduction
Gum Arabic (GA) or Acacia gum is a soluble dietary fiber obtained from the stems
and branches of the Acacia senegal and Acacia seyal plants, which grow mainly in the
African region of Sahe in Sudan [1]. It is often associated with health benefits relevant
to reducing the risk of metabolic syndrome (MetS). GA contains three different fractions
of highly-branched carbohydrate structures that vary in molecular mass and protein
content, which are believed to underlie its physiological effects. These are commonly
known as the arabinogalactan-protein, arabinogalactan, and glycoprotein fractions [2].
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However, the composition of GA may change depending on the source, climate, and soil [3].
Because of the physical properties of GA, it has been widely used in various industries
including cosmetics, textiles, ceramics, pharmaceuticals and foods [4]. GA is commonly
used in industrial food production as an emulsifier, a stabilizer, and a thickener due to
its nondigestibility, low-solution viscosity, and safety [5]. Used as a traditional remedy
for many years, several studies have described the antioxidant properties of GA and its
capacity to neutralize reactive oxygen substances [6–8]. Research also suggests it may
have an effect on lipid metabolism [9], as well as renal function [10–12] and satiety [13],
lending support to its use as an adjunct in the prevention and treatment of metabolic
syndrome. Broadly, GA appears to have a hypocholesterolemic effect, decreasing low-
density lipoproteins (LDL) and very low density lipoproteins (VLDL) without affecting
high-density lipoproteins (HDL) and triglycerides in animal models [6]. GA has shown
potential to relieve the effects of chronic renal failure by improving creatinine clearance
as well as excretion of magnesium and calcium [14]. It has also been reported to decrease
blood pressure in mice, and has been shown to lower caloric intake significantly, potentially
due to increased dietary-fiber intake increasing satiety [5]. This reduction in energy intake
makes GA a strong candidate for adjunct weight-control therapies.
Metabolic syndrome describes a cluster of conditions including increased blood pres-
sure, high blood glucose, excess body fat, and dyslipidemia occurring simultaneously [15].
Metabolic syndrome is one of the most significant risk factors for a wide range of noncom-
municable diseases (NCDs) such as cardiovascular diseases and diabetes [16]. According
to the World Health Organization (WHO), NCDs are responsible for 71 percent of deaths
globally, with cardiovascular disease being the leading cause of death, followed by cancer,
respiratory diseases, and diabetes [17]. Most NCDs share common behavioral risk factors
such as poor diet, physical inactivity, and smoking, as well as the key MetS risk factors
such as overweight, obesity, high blood sugar, and hypercholesterolemia [18]. This makes
reducing the burden of MetS a key element in the prevention of NCDs [16].
Given the significant burden of MetS and its associated risk of NCDs, there is a need
for novel interventions to help prevent its onset. This study aimed to investigate the effect
of consuming 20 g of Gum Arabic-Acacia Senegal (GA-AS) per day based on key metabolic
parameters in adults with, or at risk of, metabolic syndrome. It is the hope that the
results of this study will provide insight into the dietary effects of consistent consumption
of Gum Arabic-Acacia Senegal. It is hypothesized that GA-AS will provide benefits to
the metabolic health of the participants with regular use and will be well tolerated by
individuals taking it.
2. Materials and Methods
2.1. Study Design
The present study was a controlled, randomized, single-blind, parallel-design study
comparing an intervention group receiving 20 g of GA-AS daily for 12 weeks with a control
group receiving a daily placebo containing 1 g of pectin for the same period. The primary
endpoints of the study were blood glucose, lipid profile, blood pressure, body composition,
gastrointestinal motion, and satiety. The study was conducted at the department of Nu-
trition and Health, College of Food and Agriculture at United Arab Emirates University
(UAEU) during the period from January to May 2018. This study was conducted according
to the principles of the Helsinki declaration on human research ethics and was approved
by the UAEU scientific research ethics committee (ref. no. ERH_2016_4372).
2.2. Study Participants
Participants were recruited from the UAEU (students and staff) through face-to-face
interviews, email, social media, and printed advertisements on the campus and in the
dormitories of the university. Participants were given both verbal and written information
about the aim of the study, data to be collected, and the duration of intervention, and they
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were required to sign a written informed-consent form to participate in the study prior
to screening.
Participants were screened for eligibility at the nutrition clinic at UAEU. Participant
eligibility was based on the presence of metabolic-syndrome risk factors. Inclusion and
exclusion criteria are summarized in Table 1. Risk factors assessed included waist circumfer-
ence (females > 80 cm and males > 94 cm), systolic blood pressure (≥130 mm Hg), diastolic
blood pressure (≥80 mm Hg), blood-fasting glucose (≥100 mg/dL), HDL cholesterol level
(for female < 50 mg/dL and males < 40 mg/dL), and triglycerides level (≥150 mg/dL).
Participants with more than three risk factors, or with two risk factors and one borderline,
were included in the study. Participants were excluded from the study if they were smokers,
pregnant women, lactating women, or were taking permanent medication.
Table 1. Nutrient composition of GA per 20 g dose.











Participants were asked to complete a health-screening questionnaire that contained
questions about medical conditions and medications that might influence glucose control,
appetite, and energy expenditure. All participants signed an informed-consent form before
taking part in the study. This study was conducted according to the guidelines in the
Declaration of Helsinki. All procedures involving human subjects were approved by the
United Arab Emirates University (UAEU) Scientific Research Ethics Committee.
Participants were randomly assigned to control and intervention groups via com-
puter software, with the experimental group receiving 20 g of GA-AS powder per day
and the control group receiving 1 g of placebo (pectin) powder per day for a period of
12 weeks. This dose was selected based on previous research showing metabolic effects
with doses of 10–30 g per day for 4–12 weeks, with lipid effects being most significant after
5 weeks [3,13,19,20]. GA powder and placebo were provided in premeasured sachets, and
participants were asked to consume the GA powder or the placebo two times per day by
adding it to hot water, tea, milk, or on any meal. The nutrient composition of the study
dose of Gum Arabic is presented in Table 1. Body weight (kg), height (cm), waist circum-
ference (cm), body composition, blood glucose, blood-lipid profile, glycated hemoglobin
A1c (HbA1c), and blood pressure were measured at baseline (week 0) and 12 weeks. In
addition, participants were asked to complete a bowel-movement questionnaire and satiety
scale at the baseline and endpoint of the study.
2.3. Research Parameters
2.3.1. Anthropometric Measurements
Body weight was recorded to the nearest 0.01 kg while the subject was wearing mini-
mal clothes (as per local cultural requirements) and no shoes. Body composition was as-
sessed via a bioimpedance device (InBody720, InBody, CA, USA), providing measurement
of percentage body fat (%BF), fat mass (kg), and fat free mass (kg). Waist circumference
was measured using measuring tapes, according to standard methods at the mid-point
between inferior costal margin and superior border of the iliac crest. In obese individuals,
the measurement was taken at the level of the umbilicus [21]. Body mass index (BMI) was
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calculated as BMI = kg/m2. All measurements were taken at baseline and after 12 weeks
of intervention.
2.3.2. Diet and Physical Activity Assessment
During the study period, the participants were asked to maintain their normal lifestyle.
Participants were asked to record their dietary intake at baseline (week 0) and at week 12
of the study period. Food records were taken over three days including two weekdays
and one weekend day. Photographs of food with different portion sizes were used to help
participants estimate the correct portion size consumed. The Food Processor® Nutrition
and Fitness Software, ESHA food-analysis program (version 10.4), and the Kuwaiti Food
Composition database were used to analyze the energy and nutrient contents of the
consumed foods [22].
Physical activity level was assessed using the International Physical Activity Ques-
tionnaire (IPAQ) (Arabic and English versions) at baseline and week 12 [23].
2.3.3. Bowel Movement and Satiety Questionnaires
Participants were asked to answer a bowel-movement questionnaire including fre-
quency and intensity of constipation, bloating, diarrhea, and heartburn. A satiety ques-
tionnaire with scoring points was used to assess satiety after 60 min of ingestion of either
GA-AS or the placebo intervention. The questionnaires were administered at both baseline
and at the end of the study (adapted from [24,25]). In the satiety questionnaire, participants
answered the following questions: How did the meal (with the study treatment or placebo)
you just ate make you feel? Did it satisfy your hunger, or did you feel like you needed to
snack later? Then they rated their feelings of satiety for 60 min using a score of 100 [24,25].
2.3.4. Biochemical Parameters
A fasting, venous blood sample was collected (5 mL) by a certified phlebotomist
at baseline and at end of the study period. Fasting blood glucose (FBG), HbA1c, serum
triglyceride (TG), high-density lipoprotein cholesterol (HDLC), low-density lipoprotein
cholesterol (LDLC), and total cholesterol (TC) were analyzed using Cobas C111 automated
biochemical analyzer (Roche Diagnostics, Indianapolis, IN, USA). All data were collected
at the laboratory facilities of the Nutrition and Health Department.
2.4. Statistical Analysis
G*Power 3.1.9.2 software was used for sample-size calculation of repeated measures
ANOVA with parallel design. Power calculation identified a sample size of at least 54
participants to detect a medium-effect size (0.25) with 95% power with significance level set
at 0.05. The statistical analysis was performed using SPSS version 24.0 and results presented
as (Mean ± Standard Deviation). Repeated measures ANOVA was used to detect the main
effects of time and group on study measures. Paired t-tests and independent t-tests were
employed to compare the effect of time and groups (Control vs. Intervention), respectively.
Binary data was assessed for statistical significance with the N-1 chi square test. Results
were considered statistically significant at p-value < 0.05.
3. Results
The study sample consisted of 80 participants from the United Arab Emirates Uni-
versity, aged 18–50 years with a mean age of 25.51 ± 9.5 years, mean BMI of 33.9 ± 5.4,
and with 62.3% being female. Nineteen participants dropped out of the study due to poor
treatment compliance, with 61 ultimately completing the 12-week intervention. Dropouts
were largely due to failure to take prescribed GA or placebo, or failure to present for follow
up testing. The control group consisted of 30 participants, and the experimental group 31
(Figure 1). There were no significant differences in baseline characteristics between groups
(Table 2).
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Figure 1. Summary of study recruitment.
Table 2. Baseline characteristics of the subjects (N = 61).
Variable Con rol (n = 30)Mean ± SD
Intervention (n = 31)
Mean ± SD p-Value
Age (years) 25.6 ± 9.9 28.3 ± 11.8 0.452
Weight (kg) 91.7 ± 20.8 92.1 ± 17.4 0.948
Height (cm) 168.3 ± 11.6 164.3 ± 7.5 0.163
BMI (kg/m2) 31.9 ± 4.7 34.1 ± 5.9 0.174
Waist circumference (cm) 100.5 ± 16.1 101.2 ± 12.7 0.867
Body Fat (%) 39.7 ± 8.4 43.7 ± 7.6 0.088
Fat free ass (kg) 53.8 ± 14.5 50.9 ± 9.4 0.382
Systolic Blood Pressure (mm Hg) 114.8 ± 16 118.3 ± 17.0 .4 2
Diastolic Blood Pressure (mm Hg) 75.8 ± 9.9 81.1 ± 9.2 0.066
Physical Activity Levels
Vigorous (min/week) 11.1 ± 3.0 14.4 ± 3.2 0.683
Moderate (min/week) 59.4 ± 5.7 62.1 ± 8.9 0.117
Light (min/week) 190.2 ± 13.1 193.5 ± 3.2 0.939
Sedentary Activity (h/day) 9.20 ± 0.4 10.5 ± 0.35 0. 55
Nutritional Intake
Energy (kcal) 2142 ± 551.8 2036.9 ± 601.5 0.534
Carbohydrate (g) 256 ± 57.7 239.4 ± 84.3 0.446
Fat (g) 82.2 ± 34.1 80.5 ± 30.7 0.852
Protein (g) 81.7 ± 28.9 86.9 ± 38.4 0.609
Dietary fiber (g) 15.0 ± 9.8 17.1 ± 15.2 0.648
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Table 2. Cont.
Variable Control (n = 30)Mean ± SD
Intervention (n = 31)
Mean ± SD p-Value
Biochemical Parameters
HbA1c (%) 6.1 ± 0.9 6.0 ± 1.7 0.763
Glucose (mg/dL) 101.5 ± 14.0 105.6 ± 36.0 0.635
Triglycerides (mg/dL) 94.7 ± 41.6 100.9 ± 53.9 0.661
Total Cholesterol (mg/dL) 150.7 ± 34.3 157.9 ± 28.2 0.413
LDLC (mg/dL) 2.5 ± 0.9 2.50 ± 0.7 0.926
HDLC (mg/dL) 46.3 ± 12.1 45.1 ± 12.1 0.747
After 12 weeks of GA treatment, the experimental group showed significant decreases
in both systolic (p = 0.008) and diastolic blood pressure (0.009), as well as fat free mass
(p = 0.03), with no intragroup difference in the control group. No significant inter- or
intragroup differences were observed in BMI, waist circumference, or body fat between
baseline and week 12 (Table 3).
Table 3. Changes in physical characteristics for study population after 12 weeks.
Control Intervention IntergroupDifference (Week 12)
Variable Baseline(Mean ± SD)
Week 12




(Mean ± SD) p-Value p-Value
Weight (kg) 91.74 ± 20.8 93.0 ± 22.3 0.37 92.09 ± 17.4 91.43 ± 17.0 0.116 0.778
BMI (kg/m2) 31.92 ± 4.7 32.6 ± 5.6 0.288 34.07 ± 5.9 33.90 ± 6.0 0.465 0.43
Waist circ. (cm) 100.50 ± 16.1 100.6 ± 18.9 0.937 101.20 ± 12.7 99.07 ± 13.0 0.155 0.728
Body Fat (%) 39.72 ± 8.4 40.90 ± 8.90 0.206 43.70 ± 7.6 44.10 ± 7.8 0.094 0.198
Fat Free Mass (kg) 53.79 ± 14.5 58.80 ± 9.70 0.185 50.85 ± 9.4 55.38 ± 8.9 0.030 * 0.206
Systolic (mm Hg) 114.80 ± 16.4 117.0 ± 15.0 0.242 118.30 ± 17.0 111.30 ± 19.8 * 0.008 * 0.273
Diastolic (mm Hg) 75.8 ± 9.90 79.50 ± 9.7 0.102 81.1 ± 9.2 76.70 ± 13.2 * 0.009 * 0.419
* p = < 0.05.
3.1. Diet and Physical-Activity Assessment
After 12 weeks of GA treatment, the intervention group showed a decrease in carbohy-
drate (p = 0.008) and calorie (p = 0.014) intake and an increase in dietary fiber consumption
(p ≤ 0.001), with no intergroup change in the controls (Table 4). There were also inter-
group differences in carbohydrate (p = 0.004) and dietary-fiber (p ≤ 0.001) consumption
at 12 weeks. The intervention group also showed a trend toward lower energy intake
compared to controls after 12 weeks; however, this did not reach significance (p = 0.069).
There were no inter- or intra-group changes to physical activity parameters either in fat or
protein consumption (Table 4).
Table 4. Dietary and physical-activity characteristics of the study population.
Control Intervention Intergroup Difference(Week 12)
Variable Baseline(Mean ± SE 1)
Week 12
(Mean ± SE 1) p-Value
Baseline
(Mean ± SE 1)
Week 12
(Mean ± SE 1) p-Value p-Value
Vigorous (min/week) 11.1 ± 3.0 10.7 ± 2.8 0.101 14.4 ± 3.2 18.4 ± 6.0 0.91 0.55
Moderate (min/week) 59.4 ± 5.7 71.5 ± 16.6 0.525 62.1 ± 8.9 59.0 ± 10.2 0.665 0.709
Light (min/week) 190.2 ± 13.1 206.5 ± 14.2 0.408 193.5 ± 3.2 198.4 ± 20.6 0.923 0.863
Sedentary Activity
(h/day) 9.20 ± 0.4 10.9 ± 0.4 0.089 10.5 ± 0.35 10.7 ± 0.43 0.677 0.847
Energy (kcal) 2142 ± 62.4 2092 ± 55.0 0.644 2036.9 ± 68.0 1810 ± 62.5 * 0.014 0.069
Carbohydrate (g) 256 ± 6.5 256 ± 6.7 0.976 239.4 ± 9.5 194.1 ± 8.8 * 0.008 0.004
Fat (g) 82.2 ± 3.9 73.2 ± 3.11 0.259 80.5 ± 3.5 71.3 ± 3.2 0.139 0.815
Protein (g) 81.7 ± 3.3 87.0 ± 3.6 0.453 86.9 ± 4.3 84.9 ± 5.2 0.836 0.854
Dietary fiber (g) 15.0 ± 1.1 16.1 ± 1.2 0.829 17.1 ± 1.7 31.9 ± 1.64 * 0.001 <0.001
1 Standard Error, * p = <0.05.
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3.2. Biochemical Assessment
After 12 weeks of GA treatment, the intervention group had significantly decreased in
fasting plasma glucose (p = 0.046), with the control group showing no change; however,
there was no difference between the groups at the endpoint (p = 0.101). There were no
changes to HbA1c or blood lipid profile in either group (Table 5).
Table 5. Biochemical measurements of study population.
Control Intervention IntergroupDifference (Week 12)
Variable Baseline(Mean ± SD)
Week 12




(Mean ± SD) p-Value p-Value
HbA1c (%) 6.10 ± 0.90 6.0 ± 0.4 0.662 6.0 ± 1.7 6.00 ± 0.8 0.938 0.145
Glucose (mg/dL) 101.50 ± 14.00 99.5 ± 14.2 0.489 105.6 ± 36.0 92.90 ± 13.20 * 0.046 0.55
Triglycerides
(mg/dL) 94.70 ± 41.60 94.9 ± 41.0 0.955 100.9 ± 53.9 93.90 ± 44.0 0.936 0.832
Total Cholesterol
(mg/dL) 150.7 ± 34.30 151.2 ± 37.8 0.941 157.9 ± 28.20 152.60 ± 30.6 0.892 0.709
LDLC (mg/dL) 2.50 ± 0.90 2.3 ± 0.8 0.433 2.50 ± 0.70 2.4 ± 0.7 0.625 0.925
HDLC (mg/dL) 46.3 ± 12.1 46.2 ± 13.2 0.951 45.1 ± 12.1 44.8 ± 13.9 0.736 <0.001
* p = <0.05.
3.3. Bowel Movement
The intervention group reported significant reductions (p = 0.005) in bloating and
improvement in bowel movement (0.047) compared to the control group. Although there
were no statistically significant differences in abdominal pain, better digestion, or reduction
in nausea, the intervention rate responses were almost double those of the control group
(Table 6).
Table 6. The effect of GA on the bowel movement at week 12 in the Control and Intervention Groups.
Response Rate for
Week 12
Control (Yes, %) Intervention (Yes, %) p-Value
Improved bowel movements 33.3 54.8 0.047 *
Reduction in bloating feelings 20.0 51.6 0.005 *
Reduction in abdominal pain 10.0 22.6 0.094
Feeling of better digestion 23.3 41.9 0.062
Reduction in nausea 10.0 25.8 0.056
Satiety Scores Baseline (Mean ±SD) 60 min (Mean ±SE)
Control 44.9 ± 24.7 51.6 ± 24.2 0.174
Gum Arabic 48.7 ± 22.3 62.5 ± 27.5 0.011
* p = <0.05.
3.4. Feeling of Satiety
One hour after taking the GA treatment, the participants in the intervention group
showed a significant increase in appetite score (reflective of a decreased appetite) compared
to controls receiving the placebo treatment (p = 0.01) (Table 6).
4. Discussion
To the best of our knowledge, the current study is the first to examine the effect
of Gum Arabic on individuals with, or at risk of developing, metabolic syndrome. The
daily treatment with GA caused improvement in a number of parameters important to
modifying outcomes and risk of metabolic syndrome, including fasting plasma glucose,
blood pressure, and energy intake. However, contrary to some other studies, our trial found
no significant reduction in body weight or BMI. In one study, 30 g of GA per day for 6 weeks
caused significant reductions in BMI, body-fat percentage, and weight in adult females
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compared to placebo-treated controls [3]. Another study on daily GA administration (30 g)
for three months also found that BMI, visceral-adiposity index, and body-adiposity index
were significantly lowered in the intervention group [26]. The difference in findings may
reflect the relative size of the studies, as, while in our study these parameters did not reach
significance, there was some evidence of a trend. With a larger group, the results may have
become significant. The differences may also be due to differences in patient demographic.
In the first study, the participants were younger and generally healthier, and while in the
second study they were significantly older, they had a much lower BMI.
The demonstrated decreases in energy and carbohydrate consumption are significant
in the context of metabolic syndrome, characterized in large part by impaired glucose
metabolism and obesity. Reducing the intake of these through nonpharmacological supple-
mentation could provide a means of management or prevention of the syndrome. While
the exact mechanism underlying the behavior change is unclear, it may be due to the
increased feelings of satiety following GA administration. These findings are echoed in
another study, which showed that supplementation with two blends of GA (EmulGold1
(EG) and PreVitae1 (PV)) decreased the caloric intake significantly three hours after con-
sumption and increased subjective ratings of satiety [19]. An increase in fat free mass
(FFM) was also identified in this study. While interesting and potentially of benefit to the
population studied, these results should be interpreted with caution. The bioimpedance
device used in this study reports two-compartment FFM which measures bone, muscle,
connective tissue, and water as one. While this is a reliable measure of body fat, it is unable
to discriminate between beneficial changes in muscle or bone mass from increases in water
retention [27]. To evaluate a potential change in bone or muscle parameters, measuring
body composition by either four-compartment or dual-Xray absorptiometry (DXA) is
required. This provides some support for the clinical use of GA in the management of
obesity, potentially providing a means to lower the burden of invasive bariatric surgery or
harsh pharmacotherapeutic avenues.
Another significant finding of the study at hand was its significant impact on the blood
pressure of the participants receiving GA. As the most significant outcomes of metabolic
syndrome are cardiovascular diseases, such as myocardial infarction and stroke, interven-
tions lowering cardiac risk are particularly important. Again, the specific mechanism for
this is unclear; however, it has been reported that intake of dietary fiber, including GA, was
associated with a significant fall in mean systolic blood pressure [SBP] in normal individ-
uals who neither had hypertension nor diabetes [10]. Another study of GA treatment in
people living with diabetes also found a decrease in blood pressure with SBP decreasing
by 5.9% and diastolic blood pressure (DBP) by 5.4% [26].
Gum Arabic is a soluble fermentable fiber that has shown hypoglycemic, antioxidant
effects and improved lipid metabolism in previous studies [6,26,28]. Our data showed
a significant reduction in blood glucose in the intervention group, a key parameter of
metabolic syndrome. An animal model showed that GA has a glucose-lowering effect
in rabbits with alloxan–induced diabetes. They showed that GA (at doses of 2, 3, and
4 mg/kg) significantly reduced the blood-glucose concentration of normal but not diabetic
rabbits. They therefore concluded that GA initiated the release of insulin from pancreatic b
cells in normal rabbits [29]. Another study suggested that the glycemic effects of GA may
be due to its viscosity, which slows gastric emptying and alters the absorption kinetics in
the intestine [30]. It has also been suggested that GA may have a prebiotic effect, which
may underlie some of its metabolic effects [20], as it has recently been identified as a
novel modulator of lipid profiles in vivo. Studies of GA have also demonstrated that
consumption of 10 g/d for four weeks is associated with higher numbers of bifidobacteria
and lactobacilli [19], both of which have been associated with beneficial effects on health
in vivo.
In this study, 51% of the participants in the intervention group reported a significant
improvement in reducing bloated feelings after 12 weeks of intake of GA-AS. The interven-
tion group reported better responses in bowel movement, reduction in abdominal pain,
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better digestion, and reduction in nausea, but the results were insignificant compared
with the control group. These findings may be due to the high dietary-fiber content in
GA-AS (85%), which aids in healthy digestion and bowel movement. In addition to what
has been previously reported, GA is not degraded in the stomach and small intestine, but
undergoes complete fermentation within the cecum of rats [31,32] and humans [33]. Such
fermentation promotes bacterial proliferation, which contribute to the prebiotic effect of
GA [13,34].
5. Conclusions
Daily ingestion of 20 g of GA-AS for 12 weeks was shown to improve satiety and
significantly reduce energy and carbohydrate intakes. It also improves blood pressure,
blood glucose, and bowel movement, while increasing perceived satiety. This positions GA
as a potential addition to the management of those with or at risk of developing metabolic
syndrome. GA is a strong candidate for supplementation, as it is edible, safe, and already
widely available in industry settings. It appears to have beneficial effects in a number
of key areas relevant to improving the outcomes of those with metabolic syndrome, and
could be a means of lowering the disease burden of NCDs globally. Future large-scale trials
should evaluate the long-term use of GA in patients with metabolic syndrome to clarify its
effects as well as identify optimal dose strategies and long-term efficacy.
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